Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) and amifostine (ethyol) in head and neck squamous cell carcinomas: A-3 protocol

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 28, Issue 5, 2005, Pages 449-455

  Abitbol, Andre ^a,c   Abdel Wahab, May ^a   Harvey, Mark ^a   Lewin, Alan ^a,c   Troner, Michael ^c   Hamilton Nelson, Kara ^b   Wu, Jiuhua ^b   Markoe, Arnold ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c BAPTIST HOSPITAL OF MIAMI   (United States)

Author keywords

Chemotherapy; Head neck cancer; Hyperfractionated radiotherapy

Indexed keywords

AMIFOSTINE; CISPLATIN; FLUOROURACIL; PACLITAXEL;

ADULT; AGED; ALLERGIC REACTION; ARTICLE; ASPIRATION PNEUMONIA; BLOOD TOXICITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMA; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TOLERANCE; DYSPHAGIA; ESOPHAGUS DISEASE; ESOPHAGUS STRICTURE; FEMALE; FEVER; HEAD AND NECK CARCINOMA; HUMAN; HYPOTHYROIDISM; LARYNX DISORDER; LARYNX EDEMA; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PHARYNX DISEASE; PHASE 2 CLINICAL TRIAL; RADIATION DERMATITIS; RASH; SALIVARY GLAND DISEASE; SEPTICEMIA; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; VOMITING;

AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PACLITAXEL;

EID: 26444467033     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000164010.12931.cd     Document Type: Article

References (39)

1. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324:1685-1690.
2. Lefebvre JL, Chevalier D, Luoinski B, et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial - EORTC Head and Neck Cooperative Group. J Natl Cancer Inst. 1996;88:890-899.
3. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999;91:2081-2086.
4. Merlano M, Benasso M, Corvo R, et al. Five- year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst. 1996;88:583-589.
5. Wendt TG, Garbenhauer GG, Rodel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol. 1998;16:1318-1324.
6. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998;338:1798-1804.
7. Adelstein DJ, Adams GL, Li Y, et al. A phase III comparison of standard radiation therapy (RT) vs RT plus concurrent cisplatin (DDP) vs split-course RT plus concurrent DDp and 5-fluorouracil (5FU) in patients with unresectable squamous cell head and neck cancer (SCHNC): an intergroup study [Abstract 1624]. Proc Am Soc Clin Oncol. 2000;19:411a.
8. Bourhis J, Pignon JP, Domenge C, et al. Meta-analysis of chemotherapy in head and neck squamous cell carcinoma, on behalf of the MACH-NC collaborative group [Abstract]. Proc Am Soc Clin Oncol. 1998;16:1486.
9. El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: a meta-analysis of prospective and randomized trials. J Clin Oncol. 1996;14:838-847.
10. Munro AJ. An overview of randomized controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer. 1995;71:83-91.
11. Stell PM. Adjuvant chemotherapy for head and neck cancer. Semin Radiat Oncol. 1992;2:195-205.
12. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three metaanalyses of updated individual data. Lancet. 2000;355:949-955.
13. Weissler MC, Meilin S, Sailer SL, et al. Simultaneous chemoradiation in the treatment of advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 1992;118:806-810.
14. Dobrowsky W, Dobrowsky E, Naude J, et al. Conventional versus accelerated fractionation in head and neck cancer. Br J Cancer. 1996; 74:8279-281.
15. Abitol AA, Schwade JG, Lewin AA, et al. Hyperfractionated radiation therapy and concurrent 5-fluorouracil, cisplatin and mitomycin C in head and neck carcinoma: a pilot study. Am J Clin Oncol. 1992;15:250-255.
16. Abitol A, Sridhar K, Lewin A, et al. Hyper fractionated radiation therapy and concurrent 5-fluorouracil, cisplatin, mitomycin C (+/- G-CSF) for locally advanced head and neck carcinoma. Proceedings of ASCO. 1995;14:295.
17. Fu KK, Phillips TL, Silverberg IJ, et al. Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group Randomized Trial. J Clin Oncol. 1987;5:1410-1418.
18. Beahrs OH, Henson DE. American Joint Committee on Cancer Manual for Staging Cancer, 3rd ed. Philadelphia: JB Lippincott Co; 1988.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:457-481.
20. Abitol A, Abdel-Wahab M, Lewin A, et al. Phase I/II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin and paclitaxel (Taxol) in stage III and IV inoperable head and neck squamous cell carcinomas: A-2 protocol. Int J Radiat Oncol Biol Phys. 2002;53:942-947.
21. Kies MS, Haraf DJ, Rosen F, et al. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol. 2001; 19:1961-1969.
22. Haraf DJ, Stenson K, List M, et al. Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer. Semin Oncol. 1997; 24:S2-68-S2-71.
23. Rosenthal DI, Sinard RJ, Okani O, et al. Seven-week continuous-infusion paclitaxel with concurrent radiotherapy for locally advanced head and neck squamous cell cancer: a phase I study. Semin Oncol. 1997;24:S19-67-S19-71.
24. Rowinsky EK, Gilbert MR, McGuire WP, et al. Sequences of Taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol. 1991;9: 1692-1703.
25. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000;18:3339-3345.
26. Rades D, Fehlauer F, Bajrovic A, et al. Serious adverse effects of amifostine during radiotherapy in head & neck cancer patients. Radiother Oncol. 2004;70:261-264.
27. Antonadou D, Pepelassi M, Synodinou M, et al. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002;52: 739-747.
28. Bardet E, Martin L, Calais G, et al. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Semin Oncol. 2002;29(suppl 19):57-60.
29. Demiral AN, Yerebakan O, Simsir V, et al. Amifostine-induced toxic epidermal necrolysis during radiotherapy: a case report. Jpn J Clin Oncol. 2002;32:447-449.
30. Vardy J, Wong E, Izard M, et al. Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review. Anticancer Drugs. 2002;13:327-330.
31. Fein DA, Lee WR, Amos WR, et al. Oropharyngeal carcinoma treated with radiotherapy: a 30 year experience. Int J Radiat Oncol Biol Phys. 1996;34:289-296.
32. Bataini JP, Asselain B, Jaulerry C, et al. A multivariate primary tumor control analysis in 465 patients treated with radical radiotherapy for cancer of the tonsillar region: clinical and treatment parameters as prognostic factors. Radiother Oncol. 1989;14:265-277.
33. Hinerman RW, Parsons JT, Mendenhall WM, et al. External beam irradiation alone or combined with neck dissection for base of tongue carcinoma: an alternate to primary surgery. Laryngoscope. 1994;104: 1466-1471.
34. Perez CA, Carmichael T, Devineni VR, et al. Carcinoma of the tonsillar fossa: a nonrandomized comparison of irradiation alone or combined with surgery: long-term results. Head Neck. 1991;13:282-290.
35. Riley RW, Lee WE, Goffinet D, et al. Squamous cell carcinoma of the base of tongue. Arch Otolaryngol Head Neck Surg. 1983;91:143-150.
36. Thawley SE, Simpson JR, Perez CA, et al. Preoperative irradiation and surgery for carcinoma of the base of tongue. Arch Otol Rhinol Laryngol. 1983;92:485-491.
37. Adelstein DJ, Saxton JP, Lavertu P, et al. A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer. Preliminary results. Head Neck. 1997;19:567-575.
38. Calais G, Alfonsi M, Bardet E, et al. Radiation alone (RT) versus RT with concomitant chemotherapy (CT) in stages III and IV oropharynx carcinoma: results of the 94-01 randomized study from the French group of radiation oncology for head and neck cancer (GORTEC) [Abstract]. Int J Radiat Oncol Biol Phys. 1998;42:145.
39. Merlano M, Vitale V, Rosso R, et al. Treatment of advanced squamous cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Engl J Med. 1992;327: 1115-1121.